Statement re Letting at Point Grand, South San

Slough Estates PLC 20th April 2005 Slough Estates secures letting at Point Grand, South San Francisco Slough Estates Plc, a leading provider of flexible business space, today announces that Rinat Neuroscience has signed a lease with Slough Estates USA for 106,000 sq.ft of office and laboratory space on the Point Grand estate, South San Francisco and will take occupancy of the facility in June 2005. Rinat was formed in 2001 when Genentech, a leader in the development of therapeutic proteins, narrowed its focus and spun out its key neuroscience assets under a broad license to Rinat. Genentech invested significant R&D resources in support of these assets over 15 years and Rinat is now building on them to pioneer the development and commercialisation of proteins for the treatment of diseases and disorders of the nervous system. Ian Coull, Chief Executive of Slough Estates said: 'We are delighted to welcome Rinat to Point Grand. The facility they have leased from us forms part of the 222,000 sq. ft campus vacated by Pfizer. Phase III of the campus has been let to Exelixis and we have received enquiries for the remaining 50,000 sq. ft. of space.' Slough Estates is a leading provider of flexible business space in business parks in Western Europe and North America, with over 1500 customers occupying 2,996,967 square metres of business space, with a total value of £3.9 billion. Slough Estates' properties are in suburban locations in close proximity to the main business centres, where there is long term demand for business accommodation to serve these key economic regions. The company's main activities are currently based around London, Brussels, Paris, Düsseldorf, San Francisco and San Diego and the company continues to develop new business parks with the long term objective of building shareholder value and enhancing its reputation for quality buildings offering excellent value to customers. www.sloughestates.com For further information contact: Shared Value Limited Andrew Best / Emily Bruning Tel: 020 7321 5022 / 5027

Companies

SEGRO (SGRO)
UK 100

Latest directors dealings